GlaxoSmithKline PLC — Director's Dealing 2012

Oct 2, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For period ending October 2012

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.

On 28 September 2012, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £14.37 per Ordinary Share, and notional ADSs at a price of $46.52 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2012 to 30 September 2012:

Non Executive Director	Ordinary Shares
Sir Christopher Gent	2,348.643
Professor Sir Roy Anderson	456.681
Dr Stephanie Burns	443.463
Stacey Cartwright	326.200
Sir Crispin Davis	1,652.749
Lynn Elsenhans	570.166
Judy Lewent	221.731
Sir Deryck Maughan	886.925
Dr Daniel Podolsky	855.249
Tom de Swaan	674.148
Jing Ulrich	158.379
Sir Robert Wilson	456.681

The Company and the Non-Executive Directors were informed of these allocations on 1 October 2012.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

2 October 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: October 02, 2012

By: VICTORIA WHYTE

---

Victoria Whyte

Authorised Signatory for and on

behalf of GlaxoSmithKline plc